Short answer
Mirum Pharmaceuticals, Inc. (MIRM) filed an 8-K current report with the SEC on April 8, 2026 reporting Item EX-99.1 (Exhibit EX-99.2). Audited 2025 statements for Bluejay Therapeutics, acquired by Mirum on January 23, 2026, provide baseline financials for the transaction.
Mirum Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item EX-99.1 · Exhibit EX-99.2
- Audited 2025 statements for Bluejay Therapeutics, acquired by Mirum on January 23, 2026, provide baseline financials for the transaction
- Cash and marketable securities totaled $76.1 million against $93.7 million operating cash burn
- Net loss reached $101.7 million, with research and development expense of $87.1 million
- Going-concern doubt existed independently, but Mirum committed funding for at least one year after issuance
- Merger-related cash costs expected at $24.0 million, including $22.0 million advisory fees and $2.0 million severance costs
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Mirum Pharmaceuticals, Inc. 8-K filings
Get the next MIRM 8-K as it lands
Follow MIRM for push alerts, or ask the research agent what this filing means.